MEETING AGENDA

8:30 a.m. **Welcome/Opening Remarks**  
Francis S. Collins, M.D., Ph.D., Director, National Institutes of Health (NIH)  
*This session will provide brief introductions, followed by an overview of the NIH Opioid Research Initiative.*

9:15 a.m. **Patient/Family Perspective**  
Jessica Hulsey Nickel, President and CEO, Addiction Policy Forum  
This presentation will provide the perspective of individuals and families impacted by the opioid crisis and the importance of medications to helping solve the problem.

9:30 a.m. **Actionable Knowledge: Research Update on Opioid Use Disorder Treatment and Overdose Prevention & Reversal**  
9:30-9:50 a.m. Nora D. Volkow, M.D., Director, National Institute on Drug Abuse (NIDA)  
This presentation will highlight the progress to date and future plans for NIH-supported research on treating opioid use disorders (OUDs) and preventing/reversing overdose. Examples of existing NIH resources and initiatives to support relevant research will be discussed.

9:50-10:45 a.m. **Group Discussion**  
Participants will be encouraged to discuss their accomplishments to date as it relates to OUD treatment and overdose prevention/reversal.

10:45 a.m. **BREAK**

11:00 a.m. **OUD Treatment: Research Directions, Challenges, and Actions**  
11:00-11:10 a.m. Research Directions and Challenges  
Ivan Montoya, M.D., Acting Director, Division of Therapeutics and Medical Consequences, NIDA  
*Pre-meeting survey findings related to future research directions and challenges in developing and implementing medications for OUD treatment will be summarized.*
11:10-12:45 p.m. **Taking Action: Group Discussion**
Francis S. Collins, M.D., Ph.D., and Nora D. Volkow, M.D.
Participants will be invited to identify partnership opportunities to expedite research, development, and implementation of OUD treatment medications.

12:45 p.m. **LUNCH** (pre-purchased box lunch)

1:30 p.m. **Overdose Prevention & Reversal: Research Directions, Challenges, and Actions**

1:30-1:40 p.m. **Research Directions and Challenges**
David McCann, Ph.D., Deputy Director, Division of Therapeutics and Medical Consequences, NIDA
Pre-meeting survey findings related to future research directions will be summarized, including challenges in developing and implementing medications for overdose prevention and reversal.

1:40-3:15 p.m. **Taking Action: Group Discussion**
Francis S. Collins, M.D., Ph.D., and Nora D. Volkow, M.D.
Participants will be invited to identify partnership opportunities to expedite research, development, and implementation of overdose prevention and reversal medications.

3:15 p.m. **BREAK**

3:30 p.m. **Summary/Next Steps**
Francis S. Collins, M.D., Ph.D., and Nora D. Volkow, M.D.
Key findings and conclusions from the meeting will be summarized and next steps discussed. Participants will be encouraged to identify areas where they might play a role in expediting the research process.

4:30 p.m. **Adjourn**